153 related articles for article (PubMed ID: 25742688)
1. What investigations are needed to optimally monitor for malignancies in SLE?
Tessier-Cloutier B; Clarke AE; Pineau CA; Keeling S; Bissonauth A; Ramsey-Goldman R; Lee J; Bernatsky S
Lupus; 2015 Jul; 24(8):781-7. PubMed ID: 25742688
[TBL] [Abstract][Full Text] [Related]
2. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus.
Keeling SO; Alabdurubalnabi Z; Avina-Zubieta A; Barr S; Bergeron L; Bernatsky S; Bourre-Tessier J; Clarke A; Baril-Dionne A; Dutz J; Ensworth S; Fifi-Mah A; Fortin PR; Gladman DD; Haaland D; Hanly JG; Hiraki LT; Hussein S; Legault K; Levy D; Lim L; Matsos M; McDonald EG; Medina-Rosas J; Pardo Pardi J; Peschken C; Pineau C; Pope J; Rader T; Reynolds J; Silverman E; Tselios K; Suitner M; Urowitz M; Touma Z; Vinet E; Santesso N
J Rheumatol; 2018 Oct; 45(10):1426-1439. PubMed ID: 30173152
[TBL] [Abstract][Full Text] [Related]
3. Malignancy in systemic lupus erythematosus: what have we learned?
Bernatsky S; Ramsey-Goldman R; Clarke AE
Best Pract Res Clin Rheumatol; 2009 Aug; 23(4):539-47. PubMed ID: 19591783
[TBL] [Abstract][Full Text] [Related]
4. Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis.
Ni J; Qiu LJ; Hu LF; Cen H; Zhang M; Wen PF; Wang XS; Pan HF; Ye DQ
Lupus; 2014 Mar; 23(3):284-92. PubMed ID: 24429300
[TBL] [Abstract][Full Text] [Related]
5. Systemic lupus erythematosus and malignancies: a review article.
Tessier-Cloutier B; Clarke AE; Ramsey-Goldman R; Gordon C; Hansen JE; Bernatsky S
Rheum Dis Clin North Am; 2014 Aug; 40(3):497-506, viii. PubMed ID: 25034158
[TBL] [Abstract][Full Text] [Related]
6. Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis.
Clarke AE; Pooley N; Marjenberg Z; Langham J; Nicholson L; Langham S; Embleton N; Wang X; Desta B; Barut V; Hammond ER
Semin Arthritis Rheum; 2021 Dec; 51(6):1230-1241. PubMed ID: 34710720
[TBL] [Abstract][Full Text] [Related]
7. Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study.
Azrielant S; Tiosano S; Watad A; Mahroum N; Whitby A; Comaneshter D; Cohen AD; Amital H
Immunol Res; 2017 Apr; 65(2):464-469. PubMed ID: 28091805
[TBL] [Abstract][Full Text] [Related]
8. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
9. Determinants of Cervical Cancer Screening Patterns Among Women With Systemic Lupus Erythematosus.
Chung SH; Oshima K; Singleton M; Thomason J; Currier C; McCartney S; Singh N
J Rheumatol; 2022 Nov; 49(11):1236-1241. PubMed ID: 35970535
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of prevalence, disease characteristics and management of systemic lupus erythematosus in Australia: identifying areas of unmet need.
Nikpour M; Bridge JA; Richter S
Intern Med J; 2014 Dec; 44(12a):1170-9. PubMed ID: 25169712
[TBL] [Abstract][Full Text] [Related]
11. Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review.
Tselios K; Sheane BJ; Gladman DD; Urowitz MB
J Rheumatol; 2016 Jan; 43(1):54-65. PubMed ID: 26568591
[TBL] [Abstract][Full Text] [Related]
12. The Cancer Risk Profile of Systemic Lupus Erythematosus Patients.
Hardenbergh D; Naik R; Manno R; Azar A; Monroy Trujillo JM; Adler B; Haque U; Timlin H
J Clin Rheumatol; 2022 Jan; 28(1):e257-e262. PubMed ID: 33657590
[TBL] [Abstract][Full Text] [Related]
13. Cancer screening in patients with systemic lupus erythematosus.
Bernatsky SR; Cooper GS; Mill C; Ramsey-Goldman R; Clarke AE; Pineau CA
J Rheumatol; 2006 Jan; 33(1):45-9. PubMed ID: 16331804
[TBL] [Abstract][Full Text] [Related]
14. Managing cancer risk in patients with systemic lupus erythematous.
Ladouceur A; Bernatsky S; Ramsey-Goldman R; Clarke AE
Expert Rev Clin Immunol; 2018 Oct; 14(10):793-802. PubMed ID: 30183456
[TBL] [Abstract][Full Text] [Related]
15. [Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome].
Ampélas JF; Wattiaux MJ; Van Amerongen AP
Encephale; 2001; 27(6):588-99. PubMed ID: 11865567
[TBL] [Abstract][Full Text] [Related]
16. Lupus and cancer.
Gayed M; Bernatsky S; Ramsey-Goldman R; Clarke A; Gordon C
Lupus; 2009 May; 18(6):479-85. PubMed ID: 19395448
[TBL] [Abstract][Full Text] [Related]
17. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis.
Bizzaro N; Villalta D; Giavarina D; Tozzoli R
Autoimmun Rev; 2012 Dec; 12(2):97-106. PubMed ID: 22810055
[TBL] [Abstract][Full Text] [Related]
18. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus.
Ragnarsson O; Gröndal G; Steinsson K
Lupus; 2003; 12(9):687-91. PubMed ID: 14514131
[TBL] [Abstract][Full Text] [Related]
19. The evolving concept of SLE comorbidities.
González LA; Alarcón GS
Expert Rev Clin Immunol; 2017 Aug; 13(8):753-768. PubMed ID: 28471690
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
